These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38368224)

  • 41. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Liu D; Leung K; Jit M; Wu JT
    Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
    Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time trend and seasonality in medically attended respiratory syncytial virus (RSV) infections in US children aged 0-5 years, January 2010-January 2023.
    Wang L; Berger N; Davis PB; Kaelber DC; Volkow N; Xu R
    Fam Med Community Health; 2023 Oct; 11(4):. PubMed ID: 37844966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RSV disease in infants and young children: Can we see a brighter future?
    Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
    Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.
    Tripp RA; Power UF; Openshaw PJM; Kauvar LM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29118126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity.
    Rzymski P; Gwenzi W
    J Med Virol; 2024 Feb; 96(2):e29453. PubMed ID: 38305000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.
    Hodgson D; Pebody R; Panovska-Griffiths J; Baguelin M; Atkins KE
    BMC Med; 2020 Nov; 18(1):348. PubMed ID: 33203423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
    Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
    Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C; Scott LJ; Plosker GL
    Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current respiratory syncytial virus prevention strategies in high-risk infants.
    Weisman LE
    Pediatr Int; 2002 Oct; 44(5):475-80. PubMed ID: 12225544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.